Amylin
Executive Summary
Files registration statement with the Securities and Exchange Commission for secondary offering of 2 mil. shares of common stock, Amylin announces Sept. 29. Proceeds will be used in part to fund expanded Phase II and initial Phase III trials of AC137 as amylin replacement therapy in Type I (juvenile onset) diabetes and initial human trials of the amylin blocker AC625. After the offering, the San Diego-based diabetes and metabolic disorders R&D firm will have 19.4 mil. shares outstanding.